New Study to Examine Effects of Namenda and Caregiving for Alzheimer's
January 11, 2006
January 11, 2006 (Fisher Center for Alzheimer's Research Foundation) – The Aging and Dementia Research Center at the New York University School of Medicine is currently recruiting patients for a new study on whether individualized Alzheimer's care may boost the benefits provided by the Alzheimer's drug Namenda. People with Alzheimer's who qualify for the trial will receive Namenda at no charge, as well as free follow-up medical evaluations. In addition, some study participants will receive an individualized caregiving program consisting of home visits to get the patient exercising, as well as doing enjoyable activities and cognitive stimulation, with educational sessions for caregivers on coping with difficult situations, and a caregiver support group, to help with questions and emotional support. To learn more call Robyn Waters at 212-263-8088.
Choosing to participate in a research study is an important personal decision. For more information about clinical trials, including answers to frequently asked questions, visit the alzinfo.org Web site at www.alzinfo.org/treatment/clinicaltrial/."
In addition, it is often helpful to talk to your healthcare provider, family members, or friends about deciding to join a trial. After you have identified some trial options, the next step is to contact the study research staff and ask questions about specific trials. To learn more about this or other New York University trials, contact Robyn Waters at 212-263-8088.
To search the National Library of Medicine's clinical trials database and locate additional clinical trials investigating Alzheimer's disease, visit www.clinicaltrials.gov.
This project was supported, in part, by a grant, number 90AZ2791, from the Administration on Aging,
Department of Health and Human Services, Washington, D.C. 20201.
Grantees undertaking projects under government sponsorship are
encouraged to express freely their findings and conclusions. Points of
view or opinions do not, therefore, necessarily represent official Administration on Aging policy.
